

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1: Name and Address of Reporting Issuer

Cannvas MedTech Inc. (the “Company”)
804-750 West Pender Street
Vancouver, BC V6C 2T7

Item 2: Date of Material Change

May 4, 2018.

Item 3: News Release

A news release was filed on SEDAR (www.sedar.com) on May 9, 2018.

Item 4: Summary of Material Changes

The Company announced that it has closed a non-brokered private placement (the “**Private Placement**”) of 4,261,480 units (“**Units**”) issued at a price of \$0.25 per Unit, raising gross proceeds of CDN\$1,065,370.

The Company also announced that it has closed a debt settlement and granted options.

Item 5: Full Description of Material Change

The Company announced that it has closed a Private Placement of 4,261,480 Units issued at a price of \$0.25 per Unit, raising gross proceeds of CDN\$1,065,370.

Insiders of Cannvas subscribed for 692,000 Units, with Shawn Moniz, CEO and a director of the Company, subscribing for 272,000 Units through a company he controls; Steve Loutskou, COO and a director of the Company, subscribing for 240,000 Units through a company he controls; Miroslav Beganovic, CFO of the Company, subscribing for 100,000 Units, and Lindsay Hamelin, a director of the Company, subscribing for 80,000 Units through a company she controls. As a result, the Private Placement is a related party transaction (as defined under Multilateral Instrument 61-101 *Protection of Minority Security Holders in Special Transactions* (“**MI 61-101**”)). The Company relied upon the “Issuer Not Listed on Specified Markets” and “Fair Market Value Not More Than \$2,500,000” exemptions from the formal valuation and minority shareholder approval requirements, respectively, under MI 61-101.

All securities issued are subject to a four-month hold period. The Private Placement proceeds will be used for the continued evolution of the Company’s technology stack and platform capabilities, partnership expansion within the technology and innovation space, as well as general working capital.

The Company also announced that it has completed debt settlements whereby the Company issued a total of 202,000 common shares at a deemed value of \$0.25 per common share to certain creditors for past consulting and other services provided to Cannvas totaling approximately \$50,500.

Additionally, the Company announced that it has granted incentive stock options to purchase a total of 372,500 common shares at an exercise price of \$0.25 per share for a period of two years to certain directors, officers and consultants in accordance with the provisions of its stock option plan.

About Cannvas MedTech Inc.

Headquartered in Toronto, Ontario with an office in Vancouver, British Columbia, Cannvas MedTech is a leading business technology company within the health science space. We design and build customer-centric platforms that enable our partners and clients to harness the power of data to truly understand their customers, industry, and key business drivers.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

For further information, please contact:

Shawn Moniz, CEO

T: 1.800.489.0116

E: info@cannvasmedtech.com

Item 9: Date of Report

May 9, 2018.